<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354679</url>
  </required_header>
  <id_info>
    <org_study_id>06-013</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-06013</secondary_id>
    <nct_id>NCT00354679</nct_id>
  </id_info>
  <brief_title>Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer</brief_title>
  <official_title>Phase II Trial of Irinotecan, Cisplatin, Bevacizumab and Concurrent Radiotherapy in Locally Advanced Esophageal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different&#xD;
      ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others&#xD;
      interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the&#xD;
      growth of esophageal cancer by blocking blood flow to the tumor. Radiation therapy uses&#xD;
      high-energy x-rays to kill tumor cells. Giving chemotherapy and monoclonal antibody therapy&#xD;
      together with radiation therapy before surgery may make the tumor smaller and reduce the&#xD;
      amount of normal tissue that needs to be removed. Giving bevacizumab after surgery may kill&#xD;
      any tumor cells that remain after surgery.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving irinotecan, cisplatin, and&#xD;
      bevacizumab together with radiation therapy followed by surgery and bevacizumab works in&#xD;
      treating patients with locally advanced esophageal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the toxicity and safety of bevacizumab when given together with cisplatin,&#xD;
           irinotecan hydrochloride, and radiotherapy followed by surgery and adjuvant bevacizumab&#xD;
           in patients with locally advanced esophageal adenocarcinoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Observe the rate of pathologic complete response in patients treated with this regimen.&#xD;
&#xD;
        -  Observe overall survival, disease-free survival, and patterns of failure in these&#xD;
           patients.&#xD;
&#xD;
        -  Clarify toxicity and tolerability of this regimen.&#xD;
&#xD;
        -  Evaluate pre-treatment levels of vascular endothelial growth factor in patient serum as&#xD;
           a corollary of response to this regimen.&#xD;
&#xD;
        -  Correlate serum proteomics data with complete pathologic response.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, open-label study.&#xD;
&#xD;
        -  Induction therapy: Patients receive cisplatin IV over 30 minutes and irinotecan&#xD;
           hydrochloride IV over 30 minutes on days 1, 8, 22, and 29. Patients also receive&#xD;
           bevacizumab IV over 30-90 minutes on days 1 and 22.&#xD;
&#xD;
        -  Combination therapy and radiotherapy: Patients receive cisplatin and irinotecan&#xD;
           hydrochloride as in induction chemotherapy on days 43, 50, 64, and 71. Patients also&#xD;
           receive bevacizumab IV over 30-90 minutes on days 43 and 64. Patients undergo external&#xD;
           beam radiotherapy 5 days a week for 6 weeks beginning on day 43.&#xD;
&#xD;
        -  Surgery: Patients undergo surgery 6-8 weeks after finishing combination therapy and&#xD;
           radiotherapy.&#xD;
&#xD;
        -  Maintenance therapy: Approximately 6 weeks after surgery, patients receive bevacizumab&#xD;
           IV over 30-90 minutes every 3 weeks for 6 months.&#xD;
&#xD;
      Blood samples are obtained at baseline, after finishing chemoradiotherapy, and prior to&#xD;
      maintenance therapy and are examined by the matrix-assisted laser-desorption ionization time&#xD;
      of flight (MALDI-TOF) mass spectometry for proteomic profiling.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year, every 4&#xD;
      months for 1 year, every 6 months for 3 years, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Safety and Toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>All toxicity will be graded according to the National Cancer Institute (NCI) Common Toxicity Criteria v3.0.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy: Patients receive cisplatin IV over 30 minutes and irinotecan hydrochloride IV over 30 minutes on days 1, 8, 22, and 29. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 22.&#xD;
Combination therapy and radiotherapy: Patients receive cisplatin and irinotecan hydrochloride as in induction chemotherapy on days 43, 50, 64, and 71. Patients also receive bevacizumab IV over 30-90 minutes on days 43 and 64. Patients undergo external beam radiotherapy 5 days a week for 6 weeks beginning on day 43. Surgery: Patients undergo surgery 6-8 weeks after finishing combination therapy and radiotherapy.&#xD;
Maintenance therapy: Approximately 6 weeks after surgery, patients receive bevacizumab IV over 30-90 minutes every 3 weeks for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>proteomic profiling</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the esophagus or gastroesophageal junction&#xD;
&#xD;
               -  T1, N1, M0 or T2-4, any N, M0 esophageal carcinoma that is surgically resectable&#xD;
&#xD;
               -  Disease must be clinically limited to the esophagus or gastroesophageal junction&#xD;
&#xD;
                    -  If tumor extends below the gastroesophageal junction into the proximal&#xD;
                       stomach, 50% of the tumor must involve the distal esophagus or&#xD;
                       gastroesophageal junction&#xD;
&#xD;
          -  No carcinoma in situ (Tis) or tumors determined to be T1, N0 after endoscopy,&#xD;
             endoscopic ultrasound, or CT scan&#xD;
&#xD;
          -  No gastric cancers with minor involvement of the gastroesophageal junction or distal&#xD;
             esophagus&#xD;
&#xD;
          -  No metastatic disease, including any of the following:&#xD;
&#xD;
               -  M1a celiac or supraclavicular disease&#xD;
&#xD;
               -  Positive malignant cytology of the pleura, pericardium, or peritoneum&#xD;
&#xD;
               -  Radiographic evidence of distant organ involvement, including lung, liver, bone,&#xD;
                  or brain&#xD;
&#xD;
               -  No involvement of nonregional lymph nodes including supraclavicular or celiac&#xD;
                  lymph node metastases that cannot be contained within a radiation field&#xD;
&#xD;
          -  No biopsy-proven tumor invasion of the tracheobronchial tree or presence of&#xD;
             tracheoesophageal fistula&#xD;
&#xD;
          -  No recurrent laryngeal nerve or phrenic nerve paralysis&#xD;
&#xD;
          -  No CNS or brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  WBC ≥ 3,000/mm³&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  INR ≤ 1.5 (except for patients requiring full-dose warfarin while on bevacizumab)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times normal&#xD;
&#xD;
          -  Urine protein ≤ 1+ by urinalysis OR &lt; 1 g of protein by 24-hour urine collection&#xD;
&#xD;
          -  Calcium &lt; 12 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other prior malignancy (except for basal cell or squamous cell carcinoma of the&#xD;
             skin, in situ cervical carcinoma, or superficial transitional cell bladder carcinoma)&#xD;
             diagnosed and/or treated within the past 3 years&#xD;
&#xD;
          -  No known Gilbert's disease&#xD;
&#xD;
          -  No clinically significant hearing loss&#xD;
&#xD;
          -  No known hypersensitivity to bevacizumab or other study drugs&#xD;
&#xD;
          -  No severe comorbid conditions, including any of the following:&#xD;
&#xD;
               -  Severe uncontrolled diabetes&#xD;
&#xD;
               -  Prior stroke or cerebrovascular disease&#xD;
&#xD;
               -  Uncontrolled infection&#xD;
&#xD;
               -  Nonmalignant illness that precludes study treatment&#xD;
&#xD;
          -  No history of serious systemic disease, including any of the following:&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Uncontrolled hypertension (i.e., blood pressure &gt; 160/110 mm Hg on medication)&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
               -  Unstable symptomatic arrhythmia requiring medication&#xD;
&#xD;
                    -  Chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal&#xD;
                       supraventricular tachycardia) allowed&#xD;
&#xD;
               -  Peripheral vascular disease ≥ grade 2&#xD;
&#xD;
          -  No significant traumatic injury within the past 28 days&#xD;
&#xD;
          -  No evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  No other concurrent medical or psychiatric condition or disease that would preclude&#xD;
             study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
          -  Recovered from prior oncologic or other major surgery&#xD;
&#xD;
          -  No major surgery or open biopsy within the past 28 days&#xD;
&#xD;
          -  No fine-needle aspiration or core biopsies within the past 7 days&#xD;
&#xD;
          -  At least 1 week since prior and no concurrent participation in another experimental&#xD;
             drug study (unless Genentech sponsored)&#xD;
&#xD;
          -  No other concurrent major surgery&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent sargramostim (GM-CSF)&#xD;
&#xD;
          -  No concurrent phenytoin, carbamazepine, barbiturates, rifampin, phenobarbital,&#xD;
             Hypericum perforatum (St. John's wort), or other antiepileptic medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H. Ilson, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>July 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <results_first_submitted>January 14, 2016</results_first_submitted>
  <results_first_submitted_qc>January 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2016</results_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</title>
          <description>Irinotecan, Cisplatin, Bevacizumab and Concurrent Radiotherapy in Locally Advanced Esophageal Adenocarcinoma</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</title>
          <description>Irinotecan, Cisplatin, Bevacizumab and Concurrent Radiotherapy in Locally Advanced Esophageal Adenocarcinoma</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Safety and Toxicity</title>
        <description>All toxicity will be graded according to the National Cancer Institute (NCI) Common Toxicity Criteria v3.0.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</title>
            <description>Irinotecan, Cisplatin, Bevacizumab and Concurrent Radiotherapy in Locally Advanced Esophageal Adenocarcinoma</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Safety and Toxicity</title>
          <description>All toxicity will be graded according to the National Cancer Institute (NCI) Common Toxicity Criteria v3.0.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial flutter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CNS cerebrovascular ischemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death not associated with CTCAE term- Death NOS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dehydration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Esophagitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Febrile neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemorrhage, CNS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection, other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes (total WBC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils/granulocytes (ANC/AGC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - Chest wall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - Extremity-limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perforation, GI- Jejunum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate, low (hypophosphatemia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, low (hypokalemia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis/embolism (vascular access-related)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis/thrombus/embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, &amp; Surger</title>
          <description>Irinotecan, Cisplatin, Bevacizumab and Concurrent Radiotherapy in Locally Advanced Esophageal Adenocarcinoma</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Perforation, GI- Jejunum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term- Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain - Chest wall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain - Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Phosphate, low (hypophosphatemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Potassium, low (hypokalemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hemorrhage, CNS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Prothrombin time international normalized ratio</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Partial thromboplastin time</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia (Difficulty swallowing)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Glucose, high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Glucose, low (hypoglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Magnesium, low (hypomagnesemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Phosphate, low (hypophosphatemia)</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Potassium, high (hyperkalemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Potassium, low (hypokalemia)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Sodium, low (hyponatremia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Trglycrde, high (hypertriglyceridemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Ilson</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-888-4183</phone>
      <email>ilsond@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

